Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)
Orthopedic Regenerative Surgical Products Market Size, Share & Trends Analysis Report By Product (Allografts, Viscosupplements), By End-use (Hospitals, ASCs), By Application, By Region, And Segment Forecasts, 2023 - 2030
»óǰÄÚµå : 1321447
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2023³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ½ÃÀå ¼ºÀå ¹× µ¿Çâ

Grand View ResearchÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 56¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö 4.0%ÀÇ ¸Å·ÂÀûÀÎ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ³ëÀÎ Àα¸ÀÇ Áõ°¡, Á¤Çü¿Ü°ú Ä¡·á ¹× ½Ã¼úÀÇ ½¬¿î Á¢±Ù¼º, ±â¼ú ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Á¤Çü¿Ü°ú Áúȯ Áß ÇϳªÀÎ °ñ°üÀý¿°Àº ³ëÀÎ Àα¸(70¼¼ ÀÌ»ó)ÀÇ ¸¸¼º ÁúȯÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î ¿©°ÜÁ® ¿Ô´Âµ¥, COVID-19 ÆÒµ¥¹Í ±â°£ µ¿¾È º´¿ø ¹× Ŭ¸®´ÐÀÇ ¸¸¼º Áúȯ ȯÀÚ ¼ö °¨¼Ò, ¸¶ÄÉÆÃ ¹× ¿µ¾÷ Ȱµ¿ Áß´Ü, ¼±ÅÃÀû ¼ö¼ú ¿¬±â, »çȸÀû °Å¸® µÎ±â, »çȸÀû °Å¸®µÎ±â »çȸÀû °Å¸®µÎ±â ÇÁ·ÎÅäÄÝ·Î ÀÎÇØ Á¦Ç° ¼ö¿ä°¡ °¨¼ÒÇß½À´Ï´Ù.

¿¹¸¦ µé¾î, ¾Ö´ÏÄ« Å×¶óǻƽ½º(Anika Therapeutics)´Â COVID-19ÀÇ ¿µÇâÀ¸·Î ÀÓ»ó½ÃÇè ȯÀÚ µî·Ï¿¡ ¾î·Á¿òÀ» °ÞÀ¸¸ç ½ÇÀû°ú ¼öÀÍ¿¡ ¾Ç¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª ÀÌ È¸»ç´Â ÆÒµ¥¹Í ÀÌÈÄ ¼±ÅÃÀû ¼ö¼úÀÌ Àç°³µÇ¸é¼­ ½ÇÀû°ú »ç¾÷À» ȸº¹Çß½À´Ï´Ù. ¹Ì±¹ Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC)¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â 2040³â±îÁö Àüü Àα¸ÀÇ 26%ÀÎ ¾à 7,800¸¸ ¸íÀÇ ¼ºÀÎÀÌ °üÀý¿° Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù. °üÀý¿°ÀÇ À§ÇèÀº ³ªÀ̰¡ µé¾î°¨¿¡ µû¶ó Áõ°¡Çϸç, ¿©¼º¿¡°Ô ´õ ¸¹ÀÌ ¹ß»ýÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ À§Çè ¿äÀÎÀº ºñ¸¸Àε¥, CDC¿¡ µû¸£¸é 2017³âºÎÅÍ 2018³â±îÁö ¹Ì±¹ ³» ºñ¸¸ À¯º´·üÀº ¾à 42.4%·Î ÃßÁ¤µË´Ï´Ù. µû¶ó¼­ Á¤Çü¿Ü°ú ÁúȯÀÇ À¯º´·ü Áõ°¡, °í·ÉÈ­ Àα¸ÀÇ Áõ°¡ ¹× ºñ¸¸ »ç·Ê°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿¡ »ç¿ëµÇ´Â Á¦Ç°Àº Åëdz, °üÀýÅë, ¼¶À¯±ÙÀ°Åë, °üÀý °á¼Õ, °ñ°üÀý¿°, Àΰø°üÀý ġȯ¼ú, ¿Ü»ó µî ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ ¶ÇÇÑ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº Áúº´À¸·Î ÀÎÇÑ ÅëÁõ ¿ÏÈ­¸¦ À§ÇÑ »õ·Î¿î Àç»ý ¼Ö·ç¼ÇÀ» µµÀÔÇϱâ À§ÇÑ ¿¬±¸°³¹ß ÇÁ·ÎÁ§Æ®¿Í °°Àº ¸î °¡Áö Àü·«ÀûÀÎ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 3¿ù Amniox Medical, Inc.´Â ÅÈÁÙ°ú ³Ãµ¿ º¸Á¸µÈ ¾ç¸·À¸·Î ±¸¼ºµÈ ÀÓ»ó½ÃÇè¿ë ÀǾàǰ(IND) TTAX03-À» »ç¿ëÇÏ¿© ¼Ò¸éü °ñ°üÀý¿° ÅëÁõ ¿ÏÈ­¸¦ À§ÇÑ Åõ¿© ½ÃÇèÀ» ÁøÇàÇϱâ À§ÇØ FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. Zimmer BiometÀº InterGro DBM, PrimaGen Advanced allograft, Platform bioresorbable bone graft substitute µî ´Ù¾çÇÑ ÇÕ¼º Á¤Çü¿Ü°ú¿ë Àç»ý Á¦Ç° ¹× À̽ÄÀç Æ÷Æ®Æú¸®¿À¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. Á¦°øÇϰí ÀÖ½À´Ï´Ù.

Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ½ÃÀå : ºÎ¹® ºÐ¼®, Á¦Ç°º°, 2018-2030³â

Á¦6Àå Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ½ÃÀå ºÐ¼®, ¿ëµµº°, 2018-2030³â(¸ÅÃâ)

Á¦7Àå Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ½ÃÀå : ºÎ¹® ºÐ¼®, ÃÖÁ¾»ç¿ëº°, 2018-2030³â

Á¦8Àå Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ½ÃÀå : Áö¿ª ½ÃÀå ºÐ¼® 2018-2030³â

Á¦9Àå Á¤Çü¿Ü°ú Àç»ý¼ö¼ú¿ë Á¦Ç° ½ÃÀå - ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Orthopedic Regenerative Surgical Products Market Growth & Trends

The global orthopedic regenerative surgical products market size is anticipated to reach USD 5.63 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at an attractive CAGR of 4.0% from 2023 to 2030. The primary factors boosting the market growth include the growing older population, easy availability of orthopedic treatments & procedures, and technological advancements. For instance, osteoarthritis, an orthopedic ailment, has been considered the major factor of chronic disability in the geriatric population (aged above 70 years). The product demand was reduced during the COVID-19 pandemic owing to the low volume of patient flow for chronic ailments in hospitals & clinics, abated marketing & sales activities, postponed elective surgeries, social distancing, and lockdown protocols.

For example, Anika Therapeutics notified challenges in patient enrollment for its clinical trials owing to the pandemic, which adversely impacted the company's operating results and revenue. However, the company recovered financial performance and operations as elective surgeries restarted post-pandemic. As per the Centers for Disease Control and Prevention (CDC), approximately 78 million adults in the U.S., or 26% of the population, are projected to be diagnosed with arthritis by 2040. The risk of arthritis increases with age and is found to be more common in females. Another risk factor is obesity. According to the CDC, the prevalence of obesity in the U.S. was estimated to be around 42.4% from 2017 to 2018. Thus, the growing prevalence of orthopedic ailments and the rising aging population & obesity cases are expected to drive market growth. The products used in orthopedic regenerative surgery have a wide range of applications, including gout, joint pain, fibromyalgia, articular defects, osteoarthritis, joint replacement, and trauma.

This is also anticipated to contribute to the growth of the market. Key players in the market are involved in several strategic initiatives, including R&D projects to introduce new regenerative solutions for pain relief from diseases. For instance, in March 2021, Amniox Medical, Inc., received FDA clearance to proceed with a dosing study using its Investigational New Drug (IND) TTAX03- consisting of the umbilical cord and cryopreserved amniotic membrane, to alleviate facet joint osteoarthritis pain. The market participants offer a wide range of orthopedic products; for instance, Zimmer Biomet provides a wide portfolio of synthetic orthopedic regenerative products and allografts, such as the InterGro DBM, PrimaGen Advanced allograft, and PlatFORM bioresorbable bone graft substitute.

Orthopedic Regenerative Surgical Products Market Report Highlights

Table of Contents

Chapter 1 Methodology And Scope

Chapter 2 Executive Summary

Chapter 3 Orthopedic Regenerative Surgical Products Market Variables, Trends & Scope

Chapter 4 Orthopedic Regenerative Surgical Products Market: COVID-19 Impact Analysis

Chapter 5 Orthopedic Regenerative Surgical Products Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)

Chapter 6 Orthopedic Regenerative Surgical Products Market Analysis, By Application, 2018 - 2030 (Revenue, USD Million)

Chapter 7 Orthopedic Regenerative Surgical Products Market: Segment Analysis, By End-Use, 2018 - 2030 (USD Million)

Chapter 8 Orthopedic Regenerative Surgical Products Market: Regional Market Analysis 2018 - 2030 (USD Million)

Chapter 9 Orthopedic Regenerative Surgical Products Market - Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â